Quarterly ResultMay 12, 2026, 05:17 PM
BridgeBio Oncology Q1 Net Loss $42.1M; R&D Expenses Up 92.8%
AI Summary
BridgeBio Oncology Therapeutics reported a significant increase in net loss for Q1 2026, reaching $42.1 million, nearly double the $22.1 million loss in Q1 2025. This was primarily driven by a substantial rise in research and development expenses, which increased by 92.8% to $39.8 million. The company's cash and cash equivalents decreased to $52.7 million from $373.7 million at year-end 2025, though total liquidity including marketable securities remained strong at $388.9 million. The company completed a de-SPAC transaction in August 2025, raising $260.9 million in PIPE financing.
Key Highlights
- Net loss increased to $42.1 million in Q1 2026 from $22.1 million in Q1 2025.
- Research and development expenses rose 92.8% to $39.8 million in Q1 2026.
- General and administrative expenses increased 154.9% to $6.4 million in Q1 2026.
- Cash and cash equivalents decreased to $52.7 million as of March 31, 2026, from $373.7 million at December 31, 2025.
- Total cash, cash equivalents, and marketable securities were $388.9 million as of March 31, 2026.
- Net cash used in operating activities was $35.9 million in Q1 2026, up from $19.6 million in Q1 2025.
- The company completed a de-SPAC transaction on August 11, 2025, including a $260.9 million PIPE financing.
Price Impact
More from BBOT